Vir Biotechnology, Inc.

NasdaqGS:VIR Stock Report

Market Cap: US$827.9m

Vir Biotechnology Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:VIR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Jul 25SellUS$37,162Mark EisnerIndividual6,796US$5.47
03 Apr 25SellUS$474,239Marianne De BackerIndividual79,712US$5.95
24 Feb 25SellUS$14,766Brent SabatiniIndividual1,562US$9.45
24 Feb 25SellUS$133,936Ann HanlyIndividual14,168US$9.45
24 Feb 25SellUS$95,063George ScangosIndividual10,056US$9.45
24 Feb 25SellUS$48,590Vanina de VerneuilIndividual5,140US$9.45
24 Feb 25SellUS$152,408Marianne De BackerIndividual16,122US$9.45
18 Feb 25SellUS$107,575George ScangosIndividual10,964US$9.81
13 Feb 25SellUS$14,291Brent SabatiniIndividual1,562US$9.15
02 Dec 24SellUS$625Vanina de VerneuilIndividual76US$8.22

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VIR?
Owner TypeNumber of SharesOwnership Percentage
Private Companies10,0000.0072%
State or Government40,5470.0292%
Individual Insiders6,115,6324.4%
Public Companies8,550,9546.16%
General Public15,171,85810.9%
VC/PE Firms27,490,64619.8%
Institutions81,536,78958.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 73.3% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.6%
BlackRock, Inc.
16,153,190US$96.3m-2.35%no data
10.5%
SB Investment Advisers (UK) Limited
14,573,983US$86.9m-12.7%0.37%
9.52%
The Vanguard Group, Inc.
13,227,066US$78.8m3.28%no data
9.3%
Arch Venture Partners, L.P.
12,916,663US$77.0m0%2.73%
6.16%
GSK plc
8,550,954US$51.0m0%1.06%
3.78%
State Street Global Advisors, Inc.
5,254,712US$31.3m-8.25%no data
2.72%
George Scangos
3,777,778US$22.5m-0.94%no data
2.56%
FMR LLC
3,556,085US$21.2m60.5%no data
2.49%
Citadel Advisors LLC
3,464,917US$20.7m114%0.02%
2.17%
Dimensional Fund Advisors LP
3,007,955US$17.9m12.1%no data
1.71%
OrbiMed Advisors LLC
2,380,715US$14.2m5.89%0.19%
1.62%
Geode Capital Management, LLC
2,252,420US$13.4m-1.86%no data
0.93%
Charles Schwab Investment Management, Inc.
1,293,016US$7.7m0%no data
0.89%
The Goldman Sachs Group, Inc.
1,234,600US$7.4m0%no data
0.88%
Vicki Sato
1,224,391US$7.3m-6.71%no data
0.77%
Ikarian Capital, LLC
1,068,062US$6.4m0%1.24%
0.77%
Renaissance Technologies LLC
1,064,500US$6.3m-4.99%0.01%
0.76%
Morgan Stanley
1,051,473US$6.3m-1.5%no data
0.72%
Aberdeen Group Plc
1,006,891US$6.0m45.3%no data
0.67%
Northern Trust Global Investments
928,240US$5.5m-0.22%no data
0.6%
Schroder Investment Management Limited
840,433US$5.0m0%no data
0.57%
Artisan Partners Limited Partnership
791,611US$4.7m0%no data
0.57%
Voloridge Investment Management, LLC
789,506US$4.7m-25.5%0.02%
0.51%
Nordea Investment Management, AB
714,561US$4.3m1.45%no data
0.5%
Hudson Bay Capital Management LP
696,000US$4.1m17.7%0.03%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/02 07:37
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vir Biotechnology, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Huidong WangBarclays
Alec StranahanBofA Global Research